SBTX
Silverback Therapeutics, Inc. [SBTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SBTX Stock Summary
In the News
SBTX Financial details
Company Rating
-
Market Cap
550.43M
Income
-14.69M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
90
Optionable
No
Shortable
Yes
Earnings
29 Mar 2023
P/E
-26098.92
Forward P/E
-
PEG
2550.33
P/S
-
P/B
2117.95
P/C
-
P/FCF
-16.77
Quick Ratio
26.89
Current Ratio
27.18
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.72
EPS next Y
-
EPS next Q
-
EPS this Y
-97.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
14.29%
SMA50
14.29%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-8%
ROE
-8%
ROC
-0.11%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.8-7.545
52W High
-16.14%
52W Low
+193.5%
RSI
37
Rel Volume
0.68
Avg Volume
171.42K
Volume
116.69K
Perf Week
-25.7%
Perf Month
-18.81%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-
-
-
Volatility
0.84%, 0.66%
Prev Close
-31.98%
Price
5.87
Change
-28.68%
Company Profile
- Volume Average 171.42K
- Market Capitalization 550.43M
- Employee 90
- CEO Dr. Peter A. Thompson M.D.
- Headquarters Seattle,WA,US
- IPO Date 2020-12-03
-
Website
https://www.silverbacktx.com 
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
